Janus Henderson Group
MRTX

Janus Henderson Group’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Janus Henderson Group’s Portfolio MRTX Stock Details MRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-20,753
Closed -$1.22M – 2602
2023
Q4 		$1.22M Sell
20,753
-8,731
-30% -$491K ﹤0.01% 1526
2023
Q3 		$1.28M Buy
29,484
+10,262
+53% +$366K ﹤0.01% 1430
2023
Q2 		$695K Sell
19,222
-16
-0.1% -$659 ﹤0.01% 1803
2023
Q1 		$716K Sell
19,238
-508,471
-96% -$22.9M ﹤0.01% 1814
2022
Q4 		$23.9M Sell
527,709
-924,507
-64% -$59.8M 0.02% 527
2022
Q3 		$101M Buy
1,452,216
+720,459
+98% +$53.3M 0.04% 357
2022
Q2 		$49.1M Sell
731,757
-209,946
-22% -$13.4M 0.03% 384
2022
Q1 		$77.4M Buy
941,703
+53,635
+6% +$5.48M 0.04% 375
2021
Q4 		$130M Sell
888,068
-109,933
-11% -$17.1M 0.05% 304
2021
Q3 		$177M Sell
998,001
-71,966
-7% -$11.6M 0.08% 254
2021
Q2 		$173M Sell
1,069,967
-86,196
-7% -$13.8M 0.07% 267
2021
Q1 		$198M Buy
1,156,163
+3,594
+0.3% +$712K 0.09% 221
2020
Q4 		$253M Sell
1,152,569
-726,211
-39% -$157M 0.12% 185
2020
Q3 		$312M Sell
1,878,780
-671,594
-26% -$91.9M 0.16% 146
2020
Q2 		$291M Buy
2,550,374
+201,473
+9% +$19.5M 0.16% 141
2020
Q1 		$181M Buy
2,348,901
+391,117
+20% +$35.1M 0.12% 178
2019
Q4 		$252M Sell
1,957,784
-54,351
-3% -$5.24M 0.13% 183
2019
Q3 		$157M Buy
2,012,135
+334,596
+20% +$31.4M 0.08% 257
2019
Q2 		$173M Sell
1,677,539
-357,205
-18% -$27.8M 0.09% 245
2019
Q1 		$149M Buy
2,034,744
+956,022
+89% +$65M 0.08% 279
2018
Q4 		$45.8M Buy
1,078,722
+52,955
+5% +$2.11M 0.03% 562
2018
Q3 		$48.3M Buy
1,025,767
+363,728
+55% +$20.2M 0.03% 600
2018
Q2 		$32.6M Buy
+662,039
New +$25M 0.02% 671

Other funds holding MRTX

S
Sachetta Lynnfield, Massachusetts $206M AUM 26.19% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Janus Henderson Group's MRTX Position: Q1 2024 in Review

Janus Henderson Group sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q1 2024, closing a stake of 20,753 shares — an estimated $1.22M sold.

Janus Henderson Group first reported a position in MRTX in Q2 2018 and held it in 23 quarters. The position peaked at $312M in Q3 2020. 2 funds tracked by Wall St. Rank hold MRTX as of Q1 2024.

  • Janus Henderson Group reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • Janus Henderson Group sold 20,753 Mirati Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $1.22M.
  • Janus Henderson Group first reported a position in Mirati Therapeutics, Inc. Common Stock in Q2 2018 and held it in 23 quarters.
  • Janus Henderson Group's Mirati Therapeutics, Inc. Common Stock position peaked at $312M in Q3 2020.
  • 2 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q1 2024.

Based on Janus Henderson Group's 13F filing for Q1 2024, filed 15 May 2024.